Patents by Inventor Michael DORE

Michael DORE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
    Patent number: 11952386
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: April 9, 2024
    Assignee: NOVARTIS AG
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, John William Giraldes, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Martin Sendzik, Troy Douglas Smith, Bakary-Barry Toure, Sarah Williams
  • QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2
    Publication number: 20230167100
    Abstract: The invention disclosed herein relates to aza-quinoline compounds of Formula (I), pharmaceutical compositions comprising such compounds, and the use of such compounds for treating a disease or condition mediated by Enhancer of Zeste Homolog 2 (EZH2), Polycomb Repressive Complex 2 (PRC2), or a combination thereof.
    Type: Application
    Filed: August 10, 2021
    Publication date: June 1, 2023
    Inventors: Xuan DAI, Michael DORE, Xiang-Ju Justin GU, Ling LI, Kun Chin LIU, Sing Yeung Frankie MAK, Yuan MI, Counde OYANG, Julien PAPILLON, Wei (Vicky) QI, Xiaoxia YAN, Zhengtian YU, Ji Yue (Jeff) ZHANG, Kehao ZHAO
  • N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20220396585
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: February 23, 2021
    Publication date: December 15, 2022
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, John William Giraldes, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Martin Sendzik, Troy Douglas Smith, Bakary-Barry Toure, Sarah Williams
  • AZA-QUINOLINE COMPOUNDS AND USES THEREOF
    Publication number: 20220280509
    Abstract: Provided aza-quinoline compounds of Formula (I), pharmaceutical compositions comprising such compounds; and the use of such compounds for treating a disease or condition mediate by Enhancer of Zeste Homolog 2 (EZH2), Polycomb Repressive Complex 2 (PRC2), or a combination thereof.
    Type: Application
    Filed: September 24, 2020
    Publication date: September 8, 2022
    Inventors: Ling LI, Xuan DAI, Michael DORE, Xiang-Ju Justin GU, Kevin Kun Chin LIU, Sing Yeung Frankie MAK, Yuan MI, Counde OYANG, Julien PAPILLON, Wei (Vicky) QI, Xiaoxia YAN, Zhengtian YU, Ji Yue (Jeff) ZHANG, Kehao ZHAO
  • COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2
    Publication number: 20220089597
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: March 3, 2021
    Publication date: March 24, 2022
    Inventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
  • N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20220073537
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: November 22, 2021
    Publication date: March 10, 2022
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, John William Giraldes, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Martin Sendzik, Troy Douglas Smith, Bakary-Barry Toure, Sarah Williams
  • N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20210371429
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: February 23, 2021
    Publication date: December 2, 2021
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, John William Giraldes, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Martin Sendzik, Troy Douglas Smith, Bakary-Barry Toure, Sarah Williams
  • COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2
    Publication number: 20210309663
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: March 3, 2021
    Publication date: October 7, 2021
    Inventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
  • Toy Packaging
    Publication number: 20210213366
    Abstract: A packaging assembly for a toy figurine includes a hanging assembly and a main body. The hanging assembly includes a hook and a platform configured to support a toy figurine proximate. The main body includes an interior cavity, a top with a slot that provides access to the interior cavity, and a bottom with an opening that provides access to the interior cavity. The slot is sized to allow the hook, but not the platform, to move therethrough into or out of the interior cavity. The opening is sized to allow the hanging assembly to move therethrough into or out of the interior cavity. The toy figurine may be disposed within the interior cavity when the hanging assembly is in the first configuration. Meanwhile, the main body and the hanging assembly may resemble a toy vehicle when the hanging assembly is in the second configuration.
    Type: Application
    Filed: January 13, 2020
    Publication date: July 15, 2021
    Inventors: Michael A. Dore, Samuel C. Unsicker
  • Compounds and compositions for inhibiting the activity of SHP2
    Patent number: 10975080
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: April 13, 2021
    Assignee: NOVARTIS AG
    Inventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
  • N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
    Patent number: 10968235
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: April 6, 2021
    Assignee: NOVARTIS AG
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, John William Giraldes, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Martin Sendzik, Troy Douglas Smith, Bakary-Barry Toure, Sarah Williams
  • N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20200181168
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: May 21, 2019
    Publication date: June 11, 2020
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, John William Giraldes, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Martin Sendzik, Troy Douglas Smith, Bakary-Barry Toure, Sarah Williams
  • N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
    Patent number: 10336774
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: July 2, 2019
    Assignee: Novartis AG
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, John William Giraldes, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Martin Sendzik, Troy Douglas Smith, Bakary-Barry Toure, Sarah Williams
  • COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2
    Publication number: 20190185475
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: June 15, 2016
    Publication date: June 20, 2019
    Inventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
  • 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
    Patent number: 10301278
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: May 28, 2019
    Assignee: Novartis AG
    Inventors: Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Sarah Williams, Martin Sendzik
  • N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
    Patent number: 10077276
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: September 18, 2018
    Assignee: Novartis AG
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Troy Douglas Smith, Sarah Williams, John William Giraldes, Martin Sendzik, Bakary-Barry Toure
  • N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20180201623
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: February 20, 2018
    Publication date: July 19, 2018
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, John William Giraldes, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Martin Sendzik, Troy Douglas Smith, Bakary-Barry Toure, Sarah Williams
  • N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
    Patent number: 9938295
    Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: April 10, 2018
    Assignee: Novartis AG
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Troy Douglas Smith, Sarah Williams, John William Giraldes, Martin Sendzik, Bakary-Barry Toure
  • 1-(TRIAZIN-3-YL/PYRIDAZIN-3-YL)-PIPER(-AZINE)IDINE DERIVATIVES AND COMPOSITIONS THEREFOR FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20180065949
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: October 5, 2017
    Publication date: March 8, 2018
    Inventors: Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Sarah Williams, Martin Sendzik
  • 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
    Patent number: 9815813
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: November 14, 2017
    Assignee: Novartis AG
    Inventors: Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Sarah Williams, Martin Sendzik